Inflammation in end-stage renal failure: Could it be treated?

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 8, 2002, Pages 33-38

  Stenvinkel, Peter ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Chronic renal failure; Cytokine; Inflammation; Malnutrition

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM LESION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALNUTRITION; MORTALITY; NUTRITIONAL STATUS; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 0036060717     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_8.33     Document Type: Article

References (82)

1. Clinical epidemiology of cardiovascular disease in chronic renal failure
2. Inflammatory and atherosclerotic interactions in the depleted uremic patient
3. Atherosclerotic cardiovascular disease risks in chronic haemodialysis patients
4. Cardiovascular disease and chronic renal disease: A new paradigm
5. Atherosclerosis: An inflammatory disease
6. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in haemodialysis (HD) patients
7. Inflammation enhances cardiovascular risk and mortality in haemodialysis patients
8. Serum C-reactive (CRP) and risk of death in chronic dialysis patients
9. C-reactive protein predicts all-cause and cardiovascular mortality in haemodialysis patients
10. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients
11. C-reactive protein and chronic Chlamydia pneumonia infection-long term predictors of cardiovascular disease survival in patients on peritoneal dialysis
12. Immunologic function and survival in haemodialysis patients
13. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients
14. Inflammation is associated with carotid atherosclerosis in dialysis patients
15. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure
16. Death risk in haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
17. Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five year prospective study
18. Excerpts from the USRDS 1999 Annual Data Report
19. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis(MIA-syndrome)
20. Factors influencing malnutrition in haemodialysis patients. A cross-sectional study
21. Association of morbidity with markers of nutrition and inflammation in chronic haemodialysis patients: A prospective study
22. Influence of co-morbidity on mortality and morbidity of haemodialysis patients
23. C-reactive protein as an outcome predictor for maintenance haemodialysis patients
24. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin and peritoneal dialysis patients
25. Silent infection in clotted haemodialysis access grafts
26. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure?
27. Relationship between antibodies to peridontal pathogens and C-reactive protein (CRP) levels in haemodialysis patients
28. Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and haemodialysis patients
29. Elevated circulating levels of interleukin-6 in patients with chronic renal failure
30. Interleukin-8 in chronic renal failure and dialysis patients
31. Plasma tumour necrosis factor soluble receptors in chronic renal failure
32. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis
33. TNF-α: mRNA, plasma protein levels and soluble receptors in patients with chronic haemodialysis, on CAPD and with end-stage renal failure
34. Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients
35. Influence of nephrectomy on tumor necrosis factor clearance in murine model
36. Fate of injected interleukin 1 in rats: Sequestration and degradation in the kidney
37. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
38. Association of variables of coagulation, fibrinolysis and acutephase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
39. Effects of the kidney or kidney-pancreas transplantation on plasma pentosidine
40. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers
41. Receptors for advanced glycosylation end products in human brain: Role in brain homeostasis
42. Glucose-dependent interleukin 6 and tumor necrosis production by human peripheral blood monocytes at vitro
43. Cachectin/TNF and IL1 induced by glucose-modified proteins: Role in normal tissue remodeling
44. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship?
45. Serum interleukin-6 in long-term haemodialysed patients
46. Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation
47. Increase of C-reactive protein serum values following haemodialysis
48. The effects of the dialysis membrane on cytokine release
49. Effects of dialyser and dialysate on the acute phase response in clinical bicarbonate dialysis
50. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro haemodialysis
51. Plasma C-reactive protein in haemodialysis patients: A cross-sectional and longitudinal survey
52. Effect of the haemodialysis membrane on the inflammatory reaction in vivo
53. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
54. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction
55. C-reactive protein-mediated low-density lipoprotein uptake by macrophages
56. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age
57. Fibrin as a factor in atherogenesis
58. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo
59. Endotoxin and GM-CSF-mediated down-regulation of macrophage apo E secretion is inhibited by a TNF-specific monoclonal antibody
60. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway
61. Interleukin-6 exacerbates early atherosclerosis in mice
62. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
63. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
64. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure
65. Angiotensin-converting enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells
66. Angiotensin-converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo
67. Do ACE-inhibitors suppress tumor necrosis factors-α production in advanced chronic renal failure?
68. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
69. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
70. Moderate doses of aspirin and risk of bleeding in renal failure
71. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients
72. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
73. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
74. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double blind, placebo-controlled clinical study
75. Thalidomide treatment reduces tumour necrosis factor-α production and enhances weight gain in patients with pulmonary tuberculosis
76. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
77. Nutritional modulation of cytokine biology
78. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
79. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients
80. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes
81. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy
82. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial